OTCM
CNVVY
Market cap5.59bUSD
Oct 08, Last price
11.46USD
1D
-1.12%
1Q
0.16%
IPO
-10.12%
Name
ConvaTec Group PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ConvaTec Group Plc is a global medical technology company focused on creating, producing, and distributing a wide array of healthcare products. Their offerings span several key areas: Advanced Wound Management: This includes specialized dressings and skincare solutions for treating both acute and chronic wounds, which can arise from conditions like diabetes, prolonged immobility, venous disease, traumatic injuries, burns, or surgical interventions. Ostomy Care: The company provides vital devices, accessories, and support services for individuals who have undergone ostomy procedures, often necessitated by conditions such as colorectal or bladder cancer, inflammatory bowel disease, or obesity. Continence and Critical Care: This division offers intermittent urinary catheters and related products to help manage urinary continence issues for patients with spinal cord injuries, multiple sclerosis, spina bifida, and other urological conditions. It also supplies a range of devices crucial for intensive care units and broader hospital settings. Specialized Monitoring and Management Systems: ConvaTec develops advanced systems for managing acute fecal incontinence, meticulously monitoring urine output, and assessing intra-abdominal pressure. Disposable Medical Supplies: Their portfolio includes a variety of single-use medical items such as wound drainage systems, urine collection bags and catheters, equipment for airway management and oxygen therapy, suction apparatus, gastroenterology tubes, and securement devices. Infusion Technology: They also manufacture disposable infusion sets for insulin pumps used in diabetes care, as well as for other continuous infusion treatments. ConvaTec distributes its products globally to a diverse clientele, including pharmacies, hospitals, and various acute and post-acute healthcare providers, either directly or via a network of distributors and wholesalers. Their customer base encompasses healthcare professionals, patients, and other manufacturers. Founded in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
Related entities
Subsidiaries (6)
180 MEDICAL, INC.
CONVATEC HEALTHCARE D S.ÀR.L.
CONVATEC HOLDINGS U.K. LIMITED
CONVATEC INC.
CONVATEC INTERNATIONAL SERVICES GMBH
UNOMEDICAL A/S
Key people
Chairman of the Board · since 2016
Frank Gehres
Franchise President � Continence and Critical Care · since 2018
John Lindskog
Franchise President � Infusion Devices
Sean McGrath
Executive Vice President - Human Resources · since 2018
Robert Steele
Executive Vice President - Quality, Regulatory & Clinical Affairs · since 2014
Adam Brent Deutsch
Chief Transformation Officer & General Counsel · since 2018
Paul Moraviec
Chief Executive Officer, Executive Director · since 2014
Frank Schulkes
Chief Financial Officer, Executive Director · since 2017
Clare Bates
Company Secretary · since 2016
Chief Executive Officer, Executive Director · since 2019
Sten Scheibye
Non-Executive Director · since 2018
Thomas Vetander
Non-Executive Director
Non-Executive Independent Director · since 2017
Non-Executive Independent Director · since 2017
Headquarters & legal address
7TH FLOOR
20 EASTBOURNE TERRACE
LONDON, LND W2 6LG
GB
20 EASTBOURNE TERRACE
LONDON, LND W2 6LG
GB
Previous name
CONVATEC GROUP LIMITED
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||